A detailed history of D. E. Shaw & Co., Inc. transactions in Axogen, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 606,555 shares of AXGN stock, worth $4.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
606,555
Previous 610,988 0.73%
Holding current value
$4.56 Million
Previous $4.17 Million 17.28%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$6.63 - $10.69 $29,390 - $47,388
-4,433 Reduced 0.73%
606,555 $4.89 Million
Q4 2023

Feb 14, 2024

BUY
$3.61 - $7.76 $128,310 - $275,813
35,543 Added 6.18%
610,988 $4.17 Million
Q3 2023

Nov 14, 2023

SELL
$4.68 - $9.26 $652,190 - $1.29 Million
-139,357 Reduced 19.5%
575,445 $2.88 Million
Q2 2023

Aug 14, 2023

BUY
$8.5 - $10.38 $345,219 - $421,573
40,614 Added 6.02%
714,802 $6.53 Million
Q1 2023

May 15, 2023

SELL
$7.53 - $10.95 $267,382 - $388,823
-35,509 Reduced 5.0%
674,188 $6.37 Million
Q4 2022

Feb 14, 2023

BUY
$9.44 - $13.09 $489,558 - $678,847
51,860 Added 7.88%
709,697 $7.08 Million
Q3 2022

Nov 14, 2022

SELL
$8.14 - $12.25 $639,502 - $962,396
-78,563 Reduced 10.67%
657,837 $7.84 Million
Q2 2022

Aug 15, 2022

SELL
$6.99 - $10.0 $503,217 - $719,910
-71,991 Reduced 8.91%
736,400 $6.03 Million
Q1 2022

May 16, 2022

BUY
$7.26 - $10.7 $132,727 - $195,617
18,282 Added 2.31%
808,391 $6.42 Million
Q4 2021

Feb 14, 2022

BUY
$8.8 - $16.0 $1.59 Million - $2.88 Million
180,185 Added 29.54%
790,109 $7.4 Million
Q3 2021

Nov 15, 2021

BUY
$15.23 - $21.72 $169,951 - $242,373
11,159 Added 1.86%
609,924 $9.64 Million
Q2 2021

Aug 16, 2021

SELL
$17.8 - $23.5 $246,832 - $325,874
-13,867 Reduced 2.26%
598,765 $12.9 Million
Q1 2021

May 17, 2021

SELL
$17.18 - $22.6 $757,878 - $996,976
-44,114 Reduced 6.72%
612,632 $12.4 Million
Q4 2020

Feb 16, 2021

SELL
$11.5 - $17.96 $1.15 Million - $1.79 Million
-99,593 Reduced 13.17%
656,746 $11.8 Million
Q3 2020

Nov 16, 2020

SELL
$10.62 - $13.12 $41,322 - $51,049
-3,891 Reduced 0.51%
756,339 $8.8 Million
Q2 2020

Aug 14, 2020

BUY
$7.35 - $10.81 $341,694 - $502,546
46,489 Added 6.51%
760,230 $7.03 Million
Q1 2020

May 15, 2020

SELL
$8.38 - $17.34 $1.63 Million - $3.36 Million
-193,981 Reduced 21.37%
713,741 $7.42 Million
Q4 2019

Feb 14, 2020

BUY
$11.18 - $18.6 $1.01 Million - $1.68 Million
90,406 Added 11.06%
907,722 $16.2 Million
Q3 2019

Nov 14, 2019

BUY
$12.09 - $20.46 $2.61 Million - $4.42 Million
216,198 Added 35.97%
817,316 $10.2 Million
Q2 2019

Aug 14, 2019

BUY
$18.5 - $25.47 $5.26 Million - $7.25 Million
284,479 Added 89.84%
601,118 $11.9 Million
Q1 2019

May 15, 2019

BUY
$14.62 - $22.13 $2.34 Million - $3.55 Million
160,318 Added 102.56%
316,639 $6.67 Million
Q4 2018

Feb 14, 2019

BUY
$17.09 - $38.25 $2.67 Million - $5.98 Million
156,321 New
156,321 $3.19 Million
Q3 2018

Nov 14, 2018

SELL
$34.05 - $55.9 $562,471 - $923,412
-16,519 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$36.15 - $52.5 $167,121 - $242,707
4,623 Added 38.86%
16,519 $830,000
Q1 2018

May 15, 2018

BUY
$24.4 - $40.25 $290,262 - $478,814
11,896 New
11,896 $434,000
Q4 2017

Feb 14, 2018

SELL
$18.5 - $28.6 $447,829 - $692,320
-24,207 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$14.65 - $19.35 $354,632 - $468,405
24,207
24,207 $468,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $318M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.